Buy Rating Affirmed for Alumis Inc. on Strong Prospects for TYK2 Inhibitor ESK-001

TipRanksAug 1 02:26 ET · Ratings

Alumis Shares Are Trading Higher. The Company Announced It Initiated Onward Phase 3 Clinical Program for ESK-001.

BenzingaJul 31 14:58 ET

Top Premarket Gainers

MT NewswiresJul 30 07:50 ET

Express News | Alumis Initiates ONWARD Phase 3 Clinical Program For ESK-001 In Moderate-To-Severe Plaque Psoriasis; Co-Primary Endpoint PASI 75 And SPGA 0/1 At 24 Weeks To Support U.S. Regulatory Submission; Topline Data Expected In 2026

BenzingaJul 29 08:02 ET

Express News | Alumis: Topline Data Anticipated in 2026

ReutersJul 29 08:02 ET

Express News | Alumis: Initiates Onward Phase 3 Clinical Program Evaluating Esk-001, an Oral Tyk2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

ReutersJul 29 08:02 ET